What Is Liquid Biopsy?
The most common cause of cancer-related death is still lung cancer. To diagnose lung cancer, physicians traditionally use a tissue biopsy. In this procedure, a small tissue sample is taken from the cancer and examined under a microscope. Since this method can be difficult and invasive, an alternative method called liquid biopsy is now being explored.
A liquid biopsy is a less invasive procedure that finds tumor-related elements in the body using just a blood sample.
Although liquid biopsy cannot completely replace traditional biopsies, it is becoming increasingly popular because of its advantages, such as detecting gene mutations (changes in the genes), assessing disease severity, and monitoring treatment response. As research continues, this technology may play a bigger role in lung cancer care.
Liquid biopsies include testing of blood and other bodily fluids. These tests involve genetic analysis and can be useful for patients who cannot undergo a traditional biopsy or whose biopsy sample contains insufficient tissue.
Why Is Liquid Biopsy Useful in Lung Cancer?
In advanced cancer, it is not always practical to take tissue samples from every site where cancer has spread. However, since blood circulates throughout the body, a liquid biopsy may contain material from both the primary (initial) tumor and metastatic (cancer spread) sites.
Another advantage is that blood samples can be collected repeatedly without major risk. This allows doctors to monitor disease progression, treatment response, recurrence, and resistance to therapy.
A liquid biopsy provides a non-invasive alternative to a surgical biopsy and helps doctors learn important details about a tumor. Small traces of cancer DNA (deoxyribonucleic acid) in the blood can provide information about which treatments may work best for a patient.
Doctors can also identify specific gene mutations using liquid biopsy tests and choose the most suitable treatment at the right time. This approach is helpful because it is convenient and generally well tolerated by patients.
Most cancers contain several genetic changes, and some of these changes may not appear in every part of the tumor. Liquid biopsy can be useful in identifying mutations in the epidermal growth factor receptors (EGFR) gene, which affects about 10 to 35 percent of patients with NSCLC (non-small cell lung cancer), the most common type of lung cancer.
Experts believe that this technology could eventually impact the diagnosis and treatment of many types of cancer. In the future, liquid biopsies may even help detect cancer before symptoms appear.
Liquid biopsies are less invasive than surgical biopsies. In most cases, only about 5 mL (milliliters) of blood is required, which makes the procedure quicker and less painful.
The blood sample is then processed to obtain plasma, which is tested for tumor DNA. In the future, the usefulness of liquid biopsies will depend on whether they improve survival rates and help doctors monitor disease progression more effectively.
Will Tissue Biopsies Become Less Common in the Future?
Cancer cure may undergo a revolution thanks to liquid biopsies. Tissue biopsies are still useful, but there are obstacles to the broad application of this new strategy. Obtaining and analyzing tissue samples remains the gold standard, as unanswered questions about liquid biopsies persist because the technology is still in its early stages.
There is limited information on how tumor types and disease stages affect test accuracy.
There is not enough data on possible regional variations or bias.
We do not know whether liquid biopsy can provide a complete picture of all cell types within a tumor.
Currently, researchers are seeking answers to these questions. In addition to tissue biopsies, liquid biopsies will enable testing of more patients. According to experts, the liquid biopsy will not replace the tissue biopsy any time soon. However, liquid biopsies will serve as an additional diagnostic test alongside tissue biopsies, enabling more patients to be examined.
This new method may influence how we manage lung cancer and predict patient outcomes, but it is not yet ready for everyone. The potential must be fully explored through additional real-world clinical investigations and comparisons. In many ways, it is a win-win situation for the patient. The usefulness of liquid biopsies in the medical context needs more confirmation through clinical trials.
Medical professionals are still investigating how best to use them to select the right immune-boosting drugs. But as science progresses, scientists are discovering more about how liquid biopsies might identify mutations, indicating that this diagnostic technique has enormous promise and the ability to change the course of history.
Tissue Biopsy Versus Liquid Biopsy:
Liquid biopsy is a minimally invasive method and can be used for continuous monitoring. It also helps reduce the risk exposure associated with surgical biopsies.
Tissue samples obtained through traditional biopsy can still be stored and used for additional studies, including immunohistochemistry and immuno-oncology research.
Thanks to liquid biopsy, blood samples contain circulating tumor DNA (ctDNA) that is continuously shed into the bloodstream from various tumor sites.
Liquid biopsy is capable of analyzing an up-to-the-minute 'genetic map' of your cancer without needing surgery.
Despite these benefits, liquid biopsy has several drawbacks that limit its wider use due to the low proportion and significant fragmentation of ctDNA.
The detection of ctDNA requires more sensitive techniques than conventional methods, such as Sanger sequencing or pyrosequencing.
Conclusion
Liquid biopsy is a new diagnostic method that uses a simple blood test to reveal crucial details about tumor genetics, treatment response, and disease progression. However, a tissue biopsy is still required for a thorough microscopic analysis of the tumor. Liquid biopsy has the potential to be a useful diagnostic and monitoring technique for cancer with further investigation. If you have any questions about liquid biopsy or cancer care, you can consult a cancer specialist.
Key Takeaways
A liquid biopsy is a minimally invasive diagnostic test used to study tumor-related material in body fluids.
Liquid biopsy can also help detect genetic mutations, treatment resistance (if any), and disease status.
It can be useful for doctors when a traditional tissue biopsy is not possible. So, it helps complement rather than replace tissue biopsy in lung cancer diagnosis.
